Roivant Sciences Ltd. (ROIV) stock: key figures, P/E, revenue and dividend
Health Care · ISIN USG762791014
Roivant Sciences Ltd. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 29.05 m USD | 8.26 m USD |
| Operating income | -1.00 bn USD | -515.07 m USD |
| EBIT | -308.56 m USD | -442.69 m USD |
| Net income | -171.98 m USD | -299.77 m USD |
| Diluted EPS – continuing operations | -0.24 USD | -0.54 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
More stocks
- East Japan Railway Co (9020.T)
- Casey's (CASY)
- Church & Dwight (CHD)
- Hana Financial (086790.KS)
- Copart (CPRT)
- Banco BPM SpA (BAMI.MI)
- Koninklijke Philips NV (PHIA.AS)
- Sany Heavy Industry Co Ltd (600031.SS)
- Aker BP ASA (AKRBP.OL)
- Northern Star Resources Ltd (NST.AX)
- Alfa Laval AB (ALFA.ST)
- China Hongqiao Group Ltd (1378.HK)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.